The future of HPV testing in clinical laboratories and applied virology research

Clinical and Diagnostic Virology

Volumn 8, Issue 2, 1997, Pages 123-141

  Coutlée, François ^a,b   Mayrand, Marie Hélène ^a   Provencher, Diane ^b   Franco, Eduardo ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Cervical cancer; HPV testing; Virology

Indexed keywords

ARTICLE; CANCER SCREENING; COST; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; NONHUMAN; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS TITRATION; WART VIRUS;

DNA, VIRAL; FEMALE; GENITALIA, FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; TUMOR VIRUS INFECTIONS;

HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0031215097     PISSN: 09280197     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0197(97)00021-4     Document Type: Article

References (106)

1. Bauer H.M., Ting Y., Greer C.E.et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 265:1991;472-477.
2. Bauer HM, Greer CE, Manos MM. Determination of genital human papillomavirus infection by consensus polymerase chain reaction amplification. In: Herrington CS, McGee JOD, editors. Diagnostic Molecular Pathology, A Practical Approach. Oxford: IRL press 1992;6:131-152.
3. Bosch F.X., Manos M.M., Muñoz N.et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst. 87:1995;796-802.
4. Brown D.R., Rawlings K., Handy V.et al. Human papillomavirus detection by hybrid capture in paired cervicovaginal lavage and cervical biopsy specimens. J Med Virol. 48:1996;210-214.
5. Burk R.D., Kelly P., Feldman J.et al. De clining prevalence of cervicovaginal human papillomavirus infection with age is independant of other risk factors. Sex Transm Dis. 23:1996;333-341.
6. Burk R.D., Kadish A.S., Calderin S., Romney S.L. Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: correlation with biopsy results and papanicolaou smear. Am J Obst Gyn. 154:1986;982-989.
7. Caballero O.L., Villa L.L., Simpson J.G. Low stringency-PCR (LS-PCR) allows entirely internally standardized DNA quantitation. Nucl Acids Res. 23:1995;192-193.
8. Cavuslu S., Mant C., Starkey W.G.et al. Analytical sensitivities of Hybrid-capture, consensus and type-specific polymerase chain reactions for the detection of human papillomavirus type 16 DNA. J Med Virol. 49:1996;319-324.
9. Chua K.-L., Wiklund F., Lenner P.et al. A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer. 68:1996;54-59.
10. Cole H.M. Diagnostic and therapeutic technology assessment: human papillomavirus DNA testing in the management of cervical neoplasia. J Am Med Assoc. 270:1993;2975-2981.
11. Cornelissen M.T.E., Smits H.L., Briet M.A.et al. Uniformity of the splicing pattern of the E6/E7 transcripts in human papillomavirus type 16-transformed human fibroblasts, human cervical premalignant lesions and carcinomas. J Gen Virol. 71:1990;1243-1246.
12. ée et al., 1989.
13. Coutlée F., Bobo L., Mayur K., Yolken R.H., Visicidi R.P. Immunodetection of DNA with a biotinylated RNA probe: a study of reactivity of a monoclonal antibody to DNA-RNA hybrids. Anal Biochem. 181:1989;96-105.
14. ée et al., 1990.
15. Coutlée F., Rubalcaba E.A., Viscidi R.P., Murphey P., Lederman H.W. Quantitative detection of messenger RNA by solution hybridization and enzyme imunoassay. J Biol Chem. 265:1990;11601-11604.
16. ée et al., 1991a.
17. Coutlée F, St-Antoine P, Olivier C, et al. Inhibitors of Taq polymerase: a potential cause for discordant results for detection of HIV-1 DNA with PCR. J Infect Dis 1991a;164:817-818.
18. ée et al., 1991b.
19. Coutlée F, Shah KV, Rader JS, Currie JL, Viscidi RP. Detection of transcripts of human papillomaviruses 16 and 18 in cancer-derived cell lines and cervical biopsies by enzyme immunoassay for DNA-RNA hybrids following solution hybridization. J Clin Microbiol 1991b;29:968-974.
20. ée et al., 1991c.
21. Coutlée F, Viscidi RP, Saint-Antoine P, Kessous A, Yolken RH. The polymerase chain reaction: a new tool for the understanding of the pathogenesis and detection of HIV-1 at the molecular level. Mol Cell Probes 1991c;5:241-259.
22. ée et al., 1995.
23. Coutlée F., Provencher D., Voyer H. Detection of human papillomavirus DNA in cervical lavage specimens by a nonisotopic consensus PCR assay. J Clin Microbiol. 33:1995;1973-1978.
24. ée et al., 1997a.
25. Coutlée F, Provencher D, Gauthier J. Is there a clinical utility for HPV detection tests for screening preinvasive and invasive diesases of the uterine cervix? Germs Ideas 1997a;2:40-44.
26. ée et al., 1997b.
27. Coutlée F, Hankins C, Lapointe N, et al. Comparison betwen vaginal tampon and cervicovaginal lavage specimens collection for detection of human papillomavirus DNA by the polymerase chain reaction. J Med Virol 1997b;51:42-47.
28. Cox J.T. Clinical role of HPV testing. Obst Gynecol Clin North Am. 23:1996;811.
29. Cox J.T., Lorincz A.T., Schiffman M.H., Sherman M.E., Cullen A., Kurman R.J. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 172:1995;946-954.
30. Cox T.J., Schiffman M.H., Winzelberg A.J., Patterson J.M. An evaluation of human papillomavirus testing as part of referral to colposcopy clinics. Obstet Gynecol. 80:1992;389-395.
31. Cullen A.P., Reid R., Campion M., Lorincz A.T. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasms. J Virol. 65:1991;606-612.
32. Cuzick J., Szarewski A., Terry G.et al. Human papillomavirus testing in primary cervical screening. Lancet. 345:1995;1533-1536.
33. édy et al., 1995.
34. Czeglédy J., Iosif C., Hansson B.G., Evander M., Gergely L., Wadell G. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer? Int J Cancer. 64:1995;211-215.
35. Daniel B., Mukherjee G., Seshadri L., Vallikad E., Krishna S. Changes in the physical state and expression of human papillomavirus type 16 in the progression of cervical intraepithelial neoplasia lesions analysed by PCR. J Gen Virol. 76:1995;2589-2593.
36. de Villiers E.-M. Human pathogenic papillomavirus types: an update. Curr Opin Microbiol Immunol. 108:1994;2-9.
37. Evander M., Edlund K., Gustafsson A.et al. Human papillomavirus infection is transient in young women: population-based cohort study. J Infect Dis. 171:1995;1026-1030.
38. Fairley F.K., Chen S., Tabrazi S.N., Quinn M.A., McNeil J.J., Garland S. Tampons: a novel patient-administered method for the assessment of genital human papillomavirus infection. J Infect Dis. 165:1992;1103-1106.
39. Ferenczy A. Management of the patient with an abnormal Papanicolaou test. Recent developments. [Review]. Obstet Gynecol Clin North Am. 20:1993;189-202.
40. Ferenczy A., Franco E., Arseneau J., Wright T.C., Richart R.M. Diagnostic performance of Hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytology study. Am J Obstet Gynecol. 175:1996;651-656.
41. Franco E., Villa L.L., Ruiz A., Costa M.C. Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J Infect Dis. 172:1997;756-763.
42. Franco EL. Measurement errors in epidemiological studies of human papillomavirus and cervical cancer. The epidemiology of cervical cancer and human papillomavirus, 1992:181-197.
43. Franco E.L. Cancer causes revisited: Human papillomavirus and cervical neoplasia. J Natl Cancer Inst. 87:1995;779-780.
44. Franco E.L., Villa L.L., Rahal P., Ruiz A. Molecular variants analysis as an epidemiological tool to study persistence of cervical human papillomavirus infection. J Natl Cancer Inst. 86:1994;1558-1559.
45. Franco ELF. Epidemiology of anogenital warts and cancer. In: Crum CP, Lorincz AT, editors. Human Papillomavirus. New York: Saunders, 1996:597-623.
46. Goldberg G.L., Vermund S.H., Schiffman M.H., Ritter D.B., Spitzer C., Burk R.D. Comparison of cytobrush and cervicovaginal lavage sampling methods for the detection of genital human papillomavirus. Am J Obstet Gynecol. 161:1989;1669-1672.
47. Goldsborough M.D., McAllister P., Reid R., Temple G., Lorincz A.T. A comparison study of human papillomavirus prevalence by the polymerase chain reaction in low risk women and in a gynecology referral group at elevated risk for cervical cancer. Mol Cell Probes. 6:1992;451-457.
48. Guibinga G.H., Coutlée F., Kessous A.K., Hankins C., Lapointe N. The Canadian Women's HIV study Group. Role of herpes simplex type 2 virus in genital cancers: review of the evidence. Arch STD/HIV Res. 9:1995;163-179.
49. Hall S., Lorincz A.T., Shah F.et al. Human papillomavirus DNA detection in cervical specimens by hybrid capture: correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix. Gynecol Oncol. 62:1996;353-359.
50. Hatch K.D., Schneider A., Abdel-Nour M.W. An evaluation of human papillomavirus testing for intermediate-and high-risk types as triage before colposcopy. Am J Obstet Gynecol. 172:1995;1150-1157.
51. Herrington C.S., Evans M.F., Hallam N.F., Charnock F.M., Gray W., McGee D. Human papillomavirus status in the prediction of high-grade cervical intra-epithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities. Br J Cancer. 71:1995;206-209.
52. Hildesheim A., Schiffman M.H., Gravitt P.E.et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 169:1994;235-240.
53. Ho G.Y.F., Burk R.D., Klein S.et al. Persistant genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 87:1995;1365-1371.
54. Hsu E.M., McNicol P.J. Characterization of HPV-16 E6/E7 transcription in CasKi cells by quantitative PCR. Mol Cell Probes. 6:1992;459-466.
55. Jacobs M.V., Snidjers P.J.F., van den Brule A.J.C., Helmerhorst T.J.M., Meijer C., Walboomers J. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 35:1997;791-795.
56. Jenkins D., Sherlawjohnson C., Gallivan S. Can papilloma virus testing be used to improve cancer screening. Int J Cancer. 65:1996;768-773.
57. Johnson K, The Canadian Task Force on the Periodic Health Examination. Periodic health examinaiton, update: 1. Screening for human papillomavirus infection in asymptomatic women. Can Med Assoc J 1995;152:483-493.
58. Jones M.H., Jenkins D., Cuzick J.et al. Mild cervical dyskaryosis: safety of cytological surveillancee. Lancet. 339:1992;1440-1443.
59. Koutsky L.A., Holmes K.K., Critchlow C.W.et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New Engl J Med. 327:1992;1272-1278.
60. Ley C., Bauer H.M., Reingold A.et al. Determinants of genital human papillomavirus infection in young woman. J Natl Cancer Inst. 83:1991;997-1003.
61. Londesborough P., Ho L., Terry G., Cuzick J., Wheeler C., Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer. 69:1996;364-368.
62. Lorincz AT. Molecular methods for the detection of human papillomavirus infection. In: Crum CP, Lorincz AT, editors. Human Papillomavirus. New York: Saunders, 1996:707-731.
63. Lorincz A.T., Reid R., Jenson A.B., Greenberg M.D., Lancaster W., Kurman R.J. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 79:1992;328-337.
64. Lorincz A.T., Schiffman M.H., Jaffurs W.J., Marlow J., Quinn A.P., Temple G.F. Temporal associations of human papillomavirus infection with cervical cytologic abnormalities. Am J Obstet Gynecol. 162:1990;645-651.
65. Manos M.M., Waldman J., Zhang T.Y.et al. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J Infect Dis. 170:1994;1096-1099.
66. Manos M.M., Ting Y., Wright D.K., Lewis A.J., Broker T., Wolinski S.M. Use of the polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells. 7:1989;209-215.
67. McDougall J.K. Cofactors in the progression of HPV-associated tumors. Antibiot Chemother. 46:1994;150-164.
68. McNicol P., Guijon F., Wayne S., Hidajat R., Paraskevas M. Expression of human papillomavirus type 16 E6-E7 open reading frame varies quantitatively in biopsy tissue from different grades of cervical intraepithelial neoplasia. J Clin Microbiol. 33:1995;1169-1173.
69. Melbye M., Smith E., Wohlfahrt J.et al. Anal and cervical abnormality in women - prediction by human papillomavirus tests. Int J Cancer. 68:1996;559-564.
70. Morrison EAB, Goldberg GL, Hagan RJ, Kadish AS, Burk RD. Self-administered home cervicovaginal lavage: a novel tool for the clinical-epidemiologic investigation of genital human papillomavirus infections. Am J Obstet Gynecol 1992a;167:104-107.
71. Morrison EAB, Goldberg GL, Kadish AS, Burk RD. Polymerase chain reation detection of human papillomavirus: quantitation may improve clinical utility. J Clin Microbiol 1992b;30:2539-2543.
72. Moscicki A.-B. Comparison between methods for human papillomavirus DNA testing: a model for self-testing in young women. J Infect Dis. 167:1993;723-725.
73. Namkoong SE. Clinical application of HPV typing in cervical cancer. Int J Gynecol Obstet 1995;49 Suppl:S59-S67.
74. Nindl I., Zahm D.-M., Meijer C.J.L.M., Walboomers J.M.M., Schneider A. Human papillomavirus detection in high-grade squamous intraepithelial lesions: comparison of hybrid capture assay with a polymerase chain reaction system. Diagn Microbiol Infect Dis. 23:1995;161-164.
75. Reid R. Biology and colposcopic features of human papillomavirus-associated cervical disease. Obstet Gyn Clin North Am. 20:1993;123-149.
76. Reid R, Lorincz AT. Human papillomavirus tests. Bail Clin Obstet Gyn 1995;9:65-103.
77. Remmink A.J., Walboomers J.M.M., Helmerhorst T.J.M.et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 61:1995;306-311.
78. Resnick R.M., Cornelissen M.T.E., Wright D.K.et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst. 82:1990;1477-1484.
79. Richart R.M., Wright T.C. Controversies in the management of low-grade cervical intraepithelial neoplasia. Cancer. 71:1993;1413-1421.
80. Ritter D.B., Kadish A.S., Vermund S.H., Rommey S.L., Villari D., Burk R.D. Detection of human papillomavirus deoxyribonucleic acid in exfoliated cervicovaginal cells as a predictor of cervical neoplasia in a high-risk population. Am J Obstet Gynecol. 159:1988;1517-1525.
81. Roman A., Fife K.H. Human papillomaviruses: are we ready to type? Clin Microbiol Rev. 2:1989;166-190.
82. Rose B.R., Thompson C.H., Tattersall M.H.N., Elliott P.M., Cossart Y.E. Identification of E6,E7 transcription patterns in HPV 16-positive cervical cancers using the reverse transcription polymerase chain reaction. Gynecol Oncol. 56:1995;239-244.
83. Rozendaal L., Walboomers J.M.M., Vanderlinden J.C.et al. PCR-based high-risk HPV test in cervical cancer screening gives obective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 68:1996;766-769.
84. Schiffman M.H. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 84:1992;394-398.
85. Schiffman M.H., Bauer H.M., Hoover R.N.et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 85:1993;958-963.
86. Schiffman M.H. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 87:1995;1345-1347.
87. Schiffman M.H., Kiviat N.B., Burk R.D.et al. Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture. J Clin Microbiol. 33:1995;545-550.
88. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995;76 Suppl:1888-1901.
89. Schneider A. Natural history of genital papillomavirus infection. Intervirology. 37:1994;201-214.
90. Schneider A., Zahm D.M., Kirchmayr R., Schneider V.L. Screening for cervical intraepithelial neoplasia grade 2/3-validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol. 174:1996;1534-1541.
91. Shah K.V., Kessis T.D., Shah F., Gupta J.W., Shibata D., Jones R.W. Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive cancer. Int J Gynecol Pathol. 15:1996;127-130.
92. Shah K.V., Solomon L., Daniel R., Cohn S., Vlahov D. Comparison of PCR and Hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection. J Clin Microbiol. 35:1997;517-519.
93. Sigurdsson K., Arnadottir T., Snorradottir M., Benediktsdottir K., Saemundsson H. Human papillomavirus (HPV) in an Icelandic population: correlation of HPV DNA to cytologic and histopathologic lesions and evaluation of treatment strategies. Int J Gynecol Cancer. 6:1996;175-182.
94. Stellato G., Nieminen P., Aho H., Vesterinen E., Vaheri A., Paavonen J. Human papillomavirus infection of the female genital tract: correlation of HPV DNA with cytologic, colposcopic, and natural history findings. Eur J Gynaecol Oncol. 13:1992;262-267.
95. Stoler M.H. A brief synopsis of the role of human papillomavirus in cervical carcinogenesis. Am J Obstet Gynecol. 175:1996;1091-1098.
96. Sun XW, Ferenczy A, Johnson D, et al. Evaluation of the Hybrid Capture human papillomavirus deoxyribonucleic acid detection test. Am J Obstet Gynecol 1995a;173:1432-1437.
97. Sun XW, Koulos JP, Felix JC et al. Human papillomavirus testing in primary cervical screening. Lancet 1995b;346:636.
98. Ting Y, Manos M. Detection and typing of genital human papillomavirus. In: PCR protocols: A Guide To Methods and Applications. New York: Academic press, 1990:356-370.
99. van de Brule A.J.C., Snidjers P.J.F., Gordjin R.L.J., Bleker O.P., Meijer C.J.L.M., Walboomers J.M.M. General primer-mediated polymerase chain reaction permits the detection of sequenced and still unsequenced human papillomavirus genotypes in cervical scrapes and carcinomas. Int J Cancer. 45:1990;644-649.
100. Vermund S.H., Schiffman M.H., Goldberg G.L., Ritter D.B., Weltman A., Burk R.D. Molecular diagnosis of genital human papillomavirus infection comparison of two methods used to collect exfoliated cervical cells. Am J Obstet Gynecol. 160:1989;304-308.
101. Vossler J.L., Forbes B.A., Adelson M.D. Evaluation of the polymerase chain reaction for the detection of human papillomavirus from urine. J Med Virol. 45:1995;354-360.
102. Williams M.L., Rimm D.L., Pedigo M.A., Frable W.J. Atypical squamous cells of undetermined origin: correlative histologic and follow-up studies from an academic medical center. Diagn Cytopathol. 16:1997;1-7.
103. Wolcott M.J. Advances in nucleic acid-based detection methods. Clin Microbiol Rev. 5:1992;370-386.
104. Wright T.C., Sun X.W., Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol. 85:1995;202-210.
105. Yang X.L., Jin G., Nakao Y., Rahimtula M., Pater M.M., Pater A. Malignant transformation of HPV 16-immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int J Cancer. 65:1996;338-344.
106. zur Hausen H. Viruses in human cancers. Science. 254:1991;1167-1173.